Clinical trial
A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and…
NCT00002245 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00002245 |
|---|---|
| Title | A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients |
| Official title | Effect of Amprenavir on Carbohydrate and Lipid Metabolism in Patients With HIV Infection |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Abacavir sulfate, Amprenavir, Lamivudine |
| Start date | Apr 1, 1999 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: